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Received September 29, 2010; accepted November 9, 2010AbstractBackground: Autoimmune mechanisms and drugs used in treatment increase the risk of liver disease in patients with juvenile idiopathic arthritis
(JIA) and hepatitis A virus (HAV) vaccination is important, especially in intermediate-endemicity areas like Turkey. In our study, we aimed to
evaluate the immune response to hepatitis A vaccine and vaccine safety in children with JIA.
Methods: This study was carried out in our hospital’s Pediatric Rheumatology outpatient clinic and Healthy Child clinic between the years 2003
and 2008. The study group consisted of 47 children with JIA (23 male and 24 female) diagnosed according to International League of
Associations for Rheumatology diagnostic criteria. The control group consisted of 67 healthy children (31 female, 36 male) who did not have
a history of hepatitis A infection or vaccination. Both groups were vaccinated with two doses of hepatitis A vaccine at 6-month intervals.
Anti-HAV IgG >80 MIU was accepted as positive response.
Results: There was no significant difference between the groups in terms of age and sex. None of the patients with JIA had fever, clinical
worsening, or disease activation after vaccination. Anti-HAV IgG positivity rate was significantly higher in the control group ( p < 0.05).
Anti-HAV IgG was negative in only four cases, and they were all male patients with systemic JIA who had active disease under anti-tumor
necrosis factor treatment.
Conclusion: Hepatitis A vaccine was safe in patients with JIA, and response to vaccine did not differ between healthy children and patients with
JIA except for children with active systemic JIA receiving anti-tumor necrosis factor alpha drugs.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Hepatitis A is an acute, usually self-limiting disease of the
liver caused by hepatitis A virus (HAV). HAV is transmitted
from person to person, primarily by the fecal-oral route. The
incidence of hepatitis A is closely related to socioeconomic
development, and sero-epidemiological studies show that
prevalence of anti-HAV antibodies in the general population* Corresponding author. Dr. Muferet Erguven, Department of Pediatrics,
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doi:10.1016/j.jcma.2011.03.004varies from 15% to close to 100% in different parts of the world.
In areas of low endemicity, hepatitis A usually occurs as single
cases among persons in high-risk groups or as outbreaks
involving a small number of persons. In areas of high ende-
micity, most people are infected with HAV without symptoms
during childhood. In areas of low and intermediate endemicity,
transmission occurs primarily from person to person in the
general community, often with periodic outbreaks. In these
countries, many individuals escape early childhood infection,
but are exposed later in life, when clinical hepatitis occurs more
frequently. In these areas, most cases occur in late childhood
and early adulthood, and hepatitis A infection has more severe
clinical progress and is the most common cause of liver
transplantation.1,2hinese Medical Association. All rights reserved.
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rheumatologic disease of childhood with unknown etiology.3
Although chronic joint involvement is the most common
feature, it is a multi-systemic disease in which fever, rash,
nephritis, carditis, and uveitis can also be seen. It is diagnosed
on the basis of clinical findings and with exclusion of other
possible diseases according to American Rheumatology
College and International League of Associations for Rheu-
matology4,5 criteria. In patients with JIA, both autoimmune
mechanisms and drugs used in treatment increase the risk of
liver toxicity. Furthermore, immunosuppression increases the
risk of infection, therefore vaccination gains importance.
There are very limited data about the safety and immunoge-
nicity of hepatitis A vaccine. Many doctors believe that
vaccination increases the risk of relapse in rheumatologic
diseases. As a result, vaccination in these patients shows
significant variation and leads to insufficient immunization. In
this study, we aimed to evaluate the immune response to
hepatitis A vaccine and vaccine safety in children with JIA.2. Methods
This study was carried out in our hospital’s Pediatric
Rheumatology outpatient clinic and Healthy Child clinic
between the years 2003 and 2008.
The study group (Group 1) consisted of 47 children with
JIA (23 male and 24 female) diagnosed according to Inter-
national League of Associations for Rheumatology diagnostic
criteria that were republished after the Edmonton Arrange-
ment in 2001.6 The parents were questioned about vaccination
of their children against hepatitis A and hepatitis infection
anamnesis. Hepatitis A antibodies (anti-HAV IgM and IgG)
were studied by macro enzyme-linked immunosorbent assay
with Macro Access auto-analyzer in all of the children with no
anamnesis of vaccination and hepatitis A infection.7 Anti-
HAV IgG >80 MIU was accepted as positive response. Chil-
dren in whom anti-HAV IgG was negative were included in the
study. None of the children had anti-HAV IgM positivity.
Children with chronic disease other than JIA and children who
did not regularly come to follow-up were excluded.Table 1
Distribution of demographical features of the study and control groups
Age (yr) (mean  SD)
Sex Female
Male
HBsAb Titers (mean  SD) (median)
Humoral response to hepatitis B vaccine Negative
Positive (>10 mU/mL)
a Student t test.
b c2 test.
c p < 0.01.
SD ¼ standard deviation.The control group (Group 2) consisted of randomly
selected 67 healthy children (31 female, 36 male) with similar
age and sex as the study group who applied to our outpatient
clinic for several health certificate or screening tests and who
did not have a history of hepatitis A infection or vaccination.
Anti-HAV IgM and IgG were evaluated in all of the children.
Children with negative anti-HAV IgG were included in the
study. None of the children had anti-HAV IgM positivity.
Disease activity was evaluated with the Childhood Health
Assessment Questionnaire (CHAQ).8 Children who did not
have any complaints in the last 6 months with CHAQ scores
less than 0.5 were accepted as being in remission. Children
who had symptoms of JIA in the last 6 months and children
who had to take additional drugs with CHAQ scores higher
than 0.5 were accepted as being in active phase.
Informed consent was obtained from the parents of all of
the children. The study was approved by the ethics committee
of the hospital. Both groups were vaccinated with two doses of
hepatitis A vaccine at 6-month intervals. Anti-HAV IgG titers
were evaluated at an average of 2 months after the second dose
of hepatitis A vaccine.
NCSS 2007&PASS 2008 Statistical Software (NCSS,
Kaysville, UT, USA) was used for statistical analysis. The
qualitative data were evaluated using c2 and Fisher’s exact
test. Significance was accepted at p < 0.05 level.3. Results
This study was carried out between October 2003 and
October 2008 in our hospital’s Pediatric Rheumatology
outpatient clinic and Healthy Child clinic. The study group
consisted of 47 patients (24 female, 23 male) with JIA with
a mean age of 10.73  3.89 years, and the control group
consisted of 67 healthy children (31 female, 36 male) with
a mean age of 9.41  3.80 years. There was no statistically
significant difference between the groups in terms of age and
sex ( p > 0.05) (Table 1).
In the study group, 14.9% of the children had systemic JIA,
12.7% had rheumatoid factor-negative polyarticular JIA, 2.1%
had rheumatoid factor-positive polyarticular JIA, 36.2% hadStudy group Control group pa
10.73  3.89 9.41  3.80 0.051
n (%) n (%) pb
24 (51.1%) 31 (46.3%) 0.253
23 (48.9%) 36 (53.7%)
134.62  111.76 (113.43) 265.83  130.63 (288.64) 0.001c
n (%) n (%) pb
4 (8.5%) 1 (1.5%) 0.001c
43 (91.5%) 66 (98.5%)
Table 2
Distribution of patients with JIA in terms of disease subtypes, drugs they used
and disease activity
n %
JIA subtypes Systemic JIA 7 14.9
RF-negative polyarticular JIA 6 12.7
RF-positive polyarticular JIA 1 2.1
Oligoarticular JIA 17 36.2
Extended oligoarticular JIA 1 2.1
Enthesitis-related JIA 15 32
Drugs used Anti-TNF 4 8.5
NSAIDs 5 10.6
MTX 29 61.7
Prednisolone 12 25.5
Salazopyrine 19 40.4
MTXdPrednisolone 11 23.4
Disease activity Remission without drugs 11 23.4
Remission with drugs 28 59.6
Active 8 17
JIA ¼ juvenile idiopathic arthritis; MTX ¼ methotrexate; NSAIDs ¼ non-
steroidal anti-inflammatory drugs; RF ¼ rheumatoid factor; TNF ¼ tumor
necrosis factor.
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32% had enthesitis-related JIA (Table 2).
Five (10.6%) of the patients used non-steroidal anti-
inflammatory drugs, 4 (8.5%) anti-tumor necrosis factor (anti-
TNF) drugs (etanercept 0.4 mg/kg twice a week for 5e6
months), 29 (61.7%) methotrexate (MTX), 12 (25.5%) pred-
nisolone, 19 (40.4%) salazopyrine, and 11(23.4%) used MTX
together with prednisolone (Table 2).
Among patients with JIA, 23.4% of the patients were in
remission with drugs, 59.6% were in remission without drugs,
and 17% had active disease (Table 2).
Anti-HAV IgG positivity showed statistically significant
difference between the groups ( p < 0.05); only four of the
patients had negative titers, and they were all from the study
group. They were all male patients with active systemic JIA
and were on anti-TNF treatment (Table 3).
No side effects were encountered in any of the patients. No
reactivation was seen and there was no increment in CHAQ
scores.
4. Discussion
HAV is the most common cause of hepatitis in childhood
and an important public health problem, especially inTable 3
Distribution of anti-HAV IgG in healthy children and children with JIA after
hepatitis A vaccination
Study group Control group pb
n (%) n (%)
Anti-HAV IgG Negative 4 (8.5%) 0 0.027a
Positive 43 (91.5%) 67 (100%)
a p < 0.01.
b Fisher’s exact test.
HAV ¼ hepatitis A virus; JIA ¼ juvenile idiopathic arthritis.intermediate-endemic areas like our country.9 It is also the
most common cause of fulminant hepatic failure in Turkish
children10 as well as in many other countries around the
world.11,12 According to the World Health Organization,
approximately 1.5 million clinical cases of hepatitis A occur
worldwide annually,1 but seroprevalence data indicate that
tens of millions of HAV infections occur each year. In areas of
moderate endemicity, HAV is not transmitted as readily
because of better sanitary and living conditions, and the
average age of infection is higher in these areas than in areas
of high endemicity.13 Paradoxically, the potential for large
outbreaks of hepatitis A can be increased in comparison with
highly endemic areas, because there is a larger pool of
susceptible older children and adults (compared with high-
endemicity countries) who are at high risk of infection and
who, when infected with HAV, are likely to develop symp-
tomatic illness.14 The best way of controlling HAVendemicity
is vaccination. Hepatitis A vaccines currently licensed are
prepared from inactivated HAV and are equivalent in terms of
immunogenicity and efficacy; however, some medical condi-
tions that cause immunosuppression might reduce immune
response.
Vaccination is an important process in children and
adolescents with inflammatory rheumatologic disease. Active
infection can lead to severe problems especially in immuno-
suppressed cases. Russo et al. reported two JIA cases who
developed macrophage activation syndrome after hepatitis A
infection.15 One of them entered remission after high-dose
steroids and immunosuppressants, and the other died. In
another case from England, a 20-year-old female with Still’s
disease who had hepatitis A was diagnosed with virus-asso-
ciated hemophagocytic lymphohistiocytosis,16 and one case
from China with systemic-onset JIA developed macrophage
activation syndrome after hepatitis A infection.17
There is insufficient data on vaccine safety and efficacy in
patients with JIA. In inflammatory diseases, response to
vaccination shows significant variation and can lead to insuf-
ficient immunization. Furthermore, vaccination time has to be
carefully chosen, and disease activity must be considered.18
Among children aged 1e18 years, 97e100% had protective
antibody levels 1 month after receiving the first dose of
vaccine, and 100% had protective levels with high geometric
mean antibody concentrations 1 month after the second
dose.19,20 Antibody sensitivity differences are not clarified yet
in chronic rheumatologic diseases and immunosuppressed
patients.21e24 Among our patients, independent of disease
activitydwhether the patient was in remission with or without
drugs or had active diseasedanti-HAV IgG was positive in all
of the cases. However, because titration was not possible, we
could not make a detailed comparison between the disease
subtypes and activity. The titers were negative in only four of
the patients with active disease receiving anti-TNF drugs.
TNF-alpha, a proinflammatory cytokine, has an important
role in naturally acquired immunity, cell regulation, differenti-
ation and apoptosis. It is released from macrophages, lympho-
cytes, somatic cells and immune cells. It also has a role in B and
T lymphocytes, monocyte, and macrophage maturation. It
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and IL-7. Studies on the effects of anti-TNF drugs on immune
response to vaccination are very few. In one study by Kapeta-
novic et al. on patients with rheumatoid arthritis after influenza
vaccination, it was shown that patients treated with TNF
blockers alone or in combination with MTX and/or other
disease modifying antirheumatic drugs had lower number of
responders to the vaccine.25 However, the mechanism of action
is still under debate. During etanercept use, cellular response
and accordingly humoral response are affected and the risks of
tuberculosis, parasitic and viral infections increase. Although
low anti-HAV titers after vaccination can be related to eta-
nercept treatment, three of four patients had active disease and
were receiving immunosuppressive drugs like MTX, which can
also have a role in decreased vaccine response.
In clinical trials, the most frequently reported side effects
of hepatitis A vaccine include soreness at the injection site,
headache, and malaise.26,27 These symptoms rarely last for
more than 48 hours. None of the licensed hepatitis A vaccines
have been associated with any serious adverse events in large
prelicensure or post-marketing studies.28e30 In our patients,
we also did not encounter any side effects, even in patients
receiving anti-TNF drugs.
In conclusion, we can say that hepatitis A vaccine is safe
and immunogenic in patients with JIA, and response to
vaccine did not differ between healthy children and patients
with JIA except for children with active systemic JIA
receiving anti-TNF alpha drugs.
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